Bliss GVS Pharma slipped 1.54% to Rs 74.03 after the company informed that the US FDA issued a Form 483 with 3 minor observations post the inspection conducted at its Palghar-based manufacturing facility.

Bliss GVS Pharma declines after Palghar units gets Form 483 with 3 observations from US FDA

The company shall prepare detailed response to the observations, which will be submitted to the USFDA within the stipulated timelines.

Bliss GVS Pharma share price falls on observations from USFDA

Aveer Foods Ltd, Bliss GVS Pharma Ltd, ISMT Ltd and Radhika Jeweltech Ltd are among the other gainers in the BSE’s ‘B’ group today, 25 January 2023.

MRO-TEK Realty Ltd leads gainers in ‘B’ group

Bliss GVS Pharma reports consolidated net profit of Rs 27.94 crore in the December 2022 quarter

Bliss GVS Pharma consolidated net profit declines 34.88% in the September 2022 quarter

Bliss GVS Pharma consolidated net profit rises 6.06% in the June 2022 quarter

Ingersoll-Rand (India) Ltd, Bliss GVS Pharma Ltd, Sequent Scientific Ltd and Apar Industries Ltd are among the other gainers in the BSE’s ‘A’ group today, 15 July 2022.

ITI Ltd leads gainers in ‘A’ group

Tata Steel, Britannia Industries, Devyani International, Bank of Maharashtra, Sundaram Clayton, Elecon Engineering Company, Bliss GVS Pharma, Rane Brake Lining, Artson Engineering, Rane Engine Valve and Morarka Finance have their annual general meetings (AGMs) today. Meanwhile, Scanpoint Geomatics w…

Corporate Radar: SKF India, Whirlpool to turn ex-dividend; Tata Steel, Britannia AGMs; stock splits and more

Apar Industries Ltd, Elecon Engineering Company Ltd, Bliss GVS Pharma Ltd and Mangalore Refinery And Petrochemicals Ltd are among the other gainers in the BSE’s ‘A’ group today, 06 June 2022.

Thyrocare Technologies Ltd leads gainers in ‘A’ group

Bliss GVS Pharma consolidated net profit rises 214.58% in the March 2022 quarter

The long-term bank facilities have been revised to IVR BBB/ Stable and short-term facilities to IVR A3+.

Bliss GVS Pharma gets revision in credit ratings by Infomerics; Stock trades flat

Hasn't fared well - amongst the low performers

Performance

Seems to be overvalued vs the market average

Valuation

Lagging behind the market in financials growth

Growth

Showing good signs of profitability & efficiency

Profitability

The stock is overpriced but is not in the overbought zone

Current price is more than the intrinsic value

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Bliss GVS Pharma Limited is engaged in developing, manufacturing and marketing pharmaceutical formulations. 